Jasgit C. Sachdev
About
Jasgit C. Sachdev is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Jasgit C. Sachdev has authored 126 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 45 papers in Molecular Biology and 41 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jasgit C. Sachdev's work include Cancer Treatment and Pharmacology (21 papers), Advanced Breast Cancer Therapies (17 papers) and HER2/EGFR in Cancer Research (15 papers). Jasgit C. Sachdev is often cited by papers focused on Cancer Treatment and Pharmacology (21 papers), Advanced Breast Cancer Therapies (17 papers) and HER2/EGFR in Cancer Research (15 papers). Jasgit C. Sachdev collaborates with scholars based in United States, United Kingdom and Spain. Jasgit C. Sachdev's co-authors include Jay Stoudemire, David S. Hong, Mitesh J. Borad, Andrew Brenner, Sinil Kim, Stephen M. Smith, Andreas G. Bader, Yoon‐Koo Kang, Muhammad S. Beg and Ramesh K. Ramanathan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
In The Last Decade
Jasgit C. Sachdev
124 papers receiving 3.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jasgit C. Sachdev United States | 23 | 1.7k | 1.6k | 947 | 558 | 483 | 126 | 3.4k | ||
| Holly E. Barker United Kingdom | 16 | 1.8k 1.0× | 1.7k 1.0× | 839 0.9× | 789 1.4× | 638 1.3× | 27 | 3.9k | ||
| Ranjit S. Bindra United States | 33 | 2.6k 1.5× | 1.3k 0.8× | 1.4k 1.4× | 642 1.2× | 205 0.4× | 122 | 4.1k | ||
| Cristina R. Ferrone United States | 20 | 1.9k 1.1× | 1.8k 1.1× | 1.5k 1.5× | 616 1.1× | 576 1.2× | 29 | 4.6k | ||
| Yuri Sheinin United States | 29 | 1.2k 0.7× | 1.1k 0.7× | 453 0.5× | 867 1.6× | 576 1.2× | 60 | 2.9k | ||
| N.V. Rajeshkumar United States | 29 | 1.9k 1.1× | 2.8k 1.8× | 1.3k 1.4× | 480 0.9× | 398 0.8× | 43 | 4.3k | ||
| John Sarantopoulos United States | 28 | 1.6k 0.9× | 1.3k 0.8× | 382 0.4× | 528 0.9× | 443 0.9× | 143 | 3.2k | ||
| Andrew Sullivan United Kingdom | 13 | 1.2k 0.7× | 1.5k 1.0× | 717 0.8× | 501 0.9× | 511 1.1× | 23 | 3.4k | ||
| Jihui Hao China | 32 | 1.4k 0.8× | 1.2k 0.7× | 792 0.8× | 363 0.7× | 590 1.2× | 117 | 3.1k | ||
| Sonja Loges Germany | 35 | 2.7k 1.6× | 1.9k 1.2× | 1.4k 1.5× | 630 1.1× | 926 1.9× | 98 | 5.0k | ||
| Laura Mercatali Italy | 29 | 1.7k 1.0× | 1.8k 1.2× | 1.2k 1.3× | 768 1.4× | 294 0.6× | 108 | 3.7k |
Countries citing papers authored by Jasgit C. Sachdev
Since
Specialization
Citations
This map shows the geographic impact of Jasgit C. Sachdev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jasgit C. Sachdev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jasgit C. Sachdev more than expected).
Fields of papers citing papers by Jasgit C. Sachdev
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jasgit C. Sachdev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jasgit C. Sachdev. The network helps show where Jasgit C. Sachdev may publish in the future.
Co-authorship network of co-authors of Jasgit C. Sachdev
This figure shows the co-authorship network connecting the top 25 collaborators of Jasgit C. Sachdev. A scholar is included among the top collaborators of Jasgit C. Sachdev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jasgit C. Sachdev. Jasgit C. Sachdev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Neilan, Brett A., Marcus Fischer, Damien Garbett, et al.. (2024). Abstract B027: The MAT2A inhibitor IDE397: a novel combination backbone for urothelial cancer subjects with MTAP deficiency. Clinical Cancer Research. 30(10_Supplement). B027–B027.
2.
Falchook, Gerald S., Jasgit C. Sachdev, Sanjeev Kumar, et al.. (2023). A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors. Investigational New Drugs. 41(3). 493–502.
3.
Arend, Rebecca C., C. de Castro, Ursula A. Matulonis, et al.. (2023). DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. Gynecologic Oncology. 172. 82–91.
4.
Münster, Pamela N., Andrew E. Greenstein, Gini F. Fleming, et al.. (2022). Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clinical Cancer Research. 28(15). 3214–3224.
5.
Maitland, Michael L., Jasgit C. Sachdev, Manish Sharma, et al.. (2021). First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clinical Cancer Research. 27(16). 4511–4520.
6.
Singh, Komal, Kord M. Kober, Brenda Ernst, et al.. (2021). Multiple Gastrointestinal Symptoms Are Associated With Chemotherapy-Induced Nausea in Patients With Breast Cancer. Cancer Nursing. 45(3). 181–189.
7.
Arend, Rebecca C., Cesar M. Castro, Ursula A. Matulonis, et al.. (2021). Patients with recurrent gynecologic cancers and Wnt activating mutations demonstrated greater clinical benefit when treated with DKN-01 therapy. Gynecologic Oncology. 162. S16–S17.
8.
Mahalingam, Devalingam, Manish R. Patel, Jasgit C. Sachdev, et al.. (2020). Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. British Journal of Clinical Pharmacology. 86(9). 1836–1848.
9.
Dudek, Arkadiusz Z., Li Liu, James H. Fischer, et al.. (2020). Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. Breast Cancer Research and Treatment. 183(3). 617–627.
10.
Piha‐Paul, Sarina A., Jasgit C. Sachdev, Minal Barve, et al.. (2019). First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Clinical Cancer Research. 25(21). 6309–6319.
11.
Sachdev, Jasgit C., et al.. (2019). Update on Precision Medicine in Breast Cancer. Cancer treatment and research. 178. 45–80.
12.
Ramanathan, Ramesh K., Ronald L. Korn, Natarajan Raghunand, et al.. (2017). Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study. Clinical Cancer Research. 23(14). 3638–3648.
13.
Bono, Johann S. de, Ramesh K. Ramanathan, Lida A. Mina, et al.. (2017). Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discovery. 7(6). 620–629.
14.
Konstantinopoulos, Panagiotis A., Jasgit C. Sachdev, Lee S. Schwartzberg, et al.. (2017). Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162). Annals of Oncology. 28. v406–v407.
15.
Edelman, Martin J., et al.. (2017). P3.02c-027 Phase I and PK Study of the Folate Receptor-Targeted Small Molecule Drug Conjugate (SMDC) EC1456 in Advanced Cancer: Lung Cancer Subset. Journal of Thoracic Oncology. 12(1). S1288–S1289.
16.
Hoff, Daniel D. Von, Monica Mita, Ramesh K. Ramanathan, et al.. (2016). Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(13). 3157–3163.
17.
Sachdev, Jasgit C., et al.. (2016). A phase 1 dose-escalation study of the folic acid-tubulysin small molecule drug conjugate (SMDC) folate-tubulysin EC1456 in advanced cancer patients.. Journal of Clinical Oncology. 34(15_suppl). 2585–2585.
18.
Patnaik, Amita, Glen J. Weiss, John E. Leonard, et al.. (2015). Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(4). 827–836.
19.
Hu‐Lieskovan, Siwen, Amita Patnaik, Peter D. Eisenberg, et al.. (2015). Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. Annals of Oncology. 26. viii5–viii5.
20.
Sachdev, Jasgit C., et al.. (2012). Dantrolene Sodium for the Treatment of Aldesleukin-lnduced Rigors in a Melanoma Patient. Annals of Pharmacotherapy. 46(5). 760–760.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Holly E. Barker Breakdown of academic impact, for papers by Ranjit S. Bindra Breakdown of academic impact, for papers by Cristina R. Ferrone Breakdown of academic impact, for papers by Yuri Sheinin Breakdown of academic impact, for papers by N.V. Rajeshkumar Breakdown of academic impact, for papers by John Sarantopoulos Breakdown of academic impact, for papers by Andrew Sullivan Breakdown of academic impact, for papers by Jihui Hao Breakdown of academic impact, for papers by Sonja Loges Breakdown of academic impact, for papers by Laura Mercatali